These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 3110781

  • 1. Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy.
    Reed E, Ozols RF, Tarone R, Yuspa SH, Poirier MC.
    Proc Natl Acad Sci U S A; 1987 Jul; 84(14):5024-8. PubMed ID: 3110781
    [Abstract] [Full Text] [Related]

  • 2. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.
    Bonetti A, Apostoli P, Zaninelli M, Pavanel F, Colombatti M, Cetto GL, Franceschi T, Sperotto L, Leone R.
    Clin Cancer Res; 1996 Nov; 2(11):1829-35. PubMed ID: 9816137
    [Abstract] [Full Text] [Related]

  • 3. Relationship between patient response in ovarian and breast cancer and platinum drug-DNA adduct formation.
    Gupta-Burt S, Shamkhani H, Reed E, Tarone RE, Allegra CJ, Pai LH, Poirier MC.
    Cancer Epidemiol Biomarkers Prev; 1993 Nov; 2(3):229-34. PubMed ID: 8318875
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of platinum-DNA adduct levels relative to known prognostic variables in a cohort of ovarian cancer patients.
    Reed E, Ostchega Y, Steinberg SM, Yuspa SH, Young RC, Ozols RF, Poirier MC.
    Cancer Res; 1990 Apr 15; 50(8):2256-60. PubMed ID: 2180564
    [Abstract] [Full Text] [Related]

  • 5. The measurement of cisplatin-DNA adduct levels in testicular cancer patients.
    Reed E, Ozols RF, Tarone R, Yuspa SH, Poirier MC.
    Carcinogenesis; 1988 Oct 15; 9(10):1909-11. PubMed ID: 2458857
    [Abstract] [Full Text] [Related]

  • 6. Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry.
    Parker RJ, Gill I, Tarone R, Vionnet JA, Grunberg S, Muggia FM, Reed E.
    Carcinogenesis; 1991 Jul 15; 12(7):1253-8. PubMed ID: 2070490
    [Abstract] [Full Text] [Related]

  • 7. Platinum-DNA adducts assayed in leukocytes of patients with germ cell tumors measured by atomic absorbance spectrometry and enzyme-linked immunosorbent assay.
    Motzer RJ, Reed E, Perera F, Tang D, Shamkhani H, Poirier MC, Tsai WY, Parker RJ, Bosl GJ.
    Cancer; 1994 Jun 01; 73(11):2843-52. PubMed ID: 7514956
    [Abstract] [Full Text] [Related]

  • 8. Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis.
    Levin L, Simon R, Hryniuk W.
    J Natl Cancer Inst; 1993 Nov 03; 85(21):1732-42. PubMed ID: 8411257
    [Abstract] [Full Text] [Related]

  • 9. Quantitation of cis-diamminedichloroplatinum II (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy.
    Reed E, Yuspa SH, Zwelling LA, Ozols RF, Poirier MC.
    J Clin Invest; 1986 Feb 03; 77(2):545-50. PubMed ID: 3944268
    [Abstract] [Full Text] [Related]

  • 10. Recurrent ovarian carcinoma: retreatment utilizing combination chemotherapy including cis-diamminedichloroplatinum in patients previously responding to this agent.
    Seltzer V, Vogl S, Kaplan B.
    Gynecol Oncol; 1985 Jun 03; 21(2):167-76. PubMed ID: 3921437
    [Abstract] [Full Text] [Related]

  • 11. Characterization of the DNA damage recognized by an antiserum elicited against cis-diamminedichloroplatinum (II)-modified DNA.
    Reed E, Gupta-Burt S, Litterst CL, Poirier MC.
    Carcinogenesis; 1990 Dec 03; 11(12):2117-21. PubMed ID: 1979937
    [Abstract] [Full Text] [Related]

  • 12. Persistence of platinum-ammine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients.
    Poirier MC, Reed E, Litterst CL, Katz D, Gupta-Burt S.
    Cancer Res; 1992 Jan 01; 52(1):149-53. PubMed ID: 1727376
    [Abstract] [Full Text] [Related]

  • 13. Oxaliplatin salvage for recurrent ovarian cancer: a single institution's experience in patient populations with platinum resistant disease or a history of platinum hypersensitivity.
    Taylor SE, Beck TL, Krivak TC, Zorn KK, Kelley JL, Edwards RP.
    Gynecol Oncol; 2014 Jul 01; 134(1):68-72. PubMed ID: 24769036
    [Abstract] [Full Text] [Related]

  • 14. Determination of cisplatin 1,2-intrastrand guanine-guanine DNA adducts in human leukocytes by high-performance liquid chromatography coupled to inductively coupled plasma mass spectrometry.
    Harrington CF, Le Pla RC, Jones GD, Thomas AL, Farmer PB.
    Chem Res Toxicol; 2010 Aug 16; 23(8):1313-21. PubMed ID: 20666396
    [Abstract] [Full Text] [Related]

  • 15. Carboplatin in the treatment of ovarian cancer.
    Alberts DS, Mason-Liddil N.
    Semin Oncol; 1989 Apr 16; 16(2 Suppl 5):19-26. PubMed ID: 2655095
    [Abstract] [Full Text] [Related]

  • 16. Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates.
    Kelland LR, Mistry P, Abel G, Loh SY, O'Neill CF, Murrer BA, Harrap KR.
    Cancer Res; 1992 Jul 15; 52(14):3857-64. PubMed ID: 1617660
    [Abstract] [Full Text] [Related]

  • 17. Cis-diamminedichloroplatinum (II): second line induction chemotherapy in advanced ovarian adenocarcinoma.
    Piver MS, Barlow JJ, Lele SB, Malfetano JH, McPhee ME.
    J Surg Oncol; 1983 Dec 15; 24(4):329-31. PubMed ID: 6418977
    [Abstract] [Full Text] [Related]

  • 18. Drug-induced DNA modification in buccal cells of cancer patients receiving carboplatin and cisplatin combination chemotherapy, as determined by an immunocytochemical method: interindividual variation and correlation with disease response.
    Blommaert FA, Michael C, Terheggen PM, Muggia FM, Kortes V, Schornagel JH, Hart AA, den Engelse L.
    Cancer Res; 1993 Dec 01; 53(23):5669-75. PubMed ID: 8242622
    [Abstract] [Full Text] [Related]

  • 19. Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation.
    Fichtinger-Schepman AM, van der Velde-Visser SD, van Dijk-Knijnenburg HC, van Oosterom AT, Baan RA, Berends F.
    Cancer Res; 1990 Dec 15; 50(24):7887-94. PubMed ID: 2253228
    [Abstract] [Full Text] [Related]

  • 20. A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy.
    Darcy KM, Tian C, Reed E.
    Cancer Res; 2007 May 01; 67(9):4474-81. PubMed ID: 17483363
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.